Cocrystal Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update
12 nov. 2019 08h35 HE
|
Cocrystal Pharma, Inc.
– Following new positive data from Phase 2a study, Company outlines next steps in clinical development plan for lead program CC-31244 for ultrashort treatment of hepatitis C (HepC) – –...
Cocrystal Pharma Presents Positive Data from U.S. Phase 2a Study of CC-31244 Demonstrating Ability to Identify Patients More Likely to Respond to Ultrashort Treatment of HCV
11 nov. 2019 08h35 HE
|
Cocrystal Pharma, Inc.
- New data presented at the American Association for the Study of Liver Diseases (AASLD) 2019 Liver Meeting - - Patients that achieved SVR had significantly higher frequencies of terminally...
Cocrystal Pharma Presents Data at the 26th International Symposium on Hepatitis C Virus and Related Viruses
08 oct. 2019 09h15 HE
|
Cocrystal Pharma, Inc.
- Novel class of HCV antivirals targeting the NS3 helicase that can be studied for the treatment of chronic HCV infection developed utilizing Company’s unique structure-based drug design platform...
Cocrystal Pharma Commences Patient Enrollment for Hong Kong Phase 2a Study of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
20 mai 2019 08h05 HE
|
Cocrystal Pharma, Inc.
- Humanity & Health Research Centre conducting differentiated Phase 2a study evaluating CC-31244 for the ultra-short treatment of hepatitis C (HepC) - Asia market represents one of the largest...
Cocrystal Pharma Announces Closing of Private Placement
11 mars 2019 08h30 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, March 11, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Announces Clinical Trial Agreement for Investigator-Initiated Phase 2a Study in Hong Kong of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
08 oct. 2018 08h00 HE
|
Cocrystal Pharma, Inc.
- Humanity & Health Research Centre to conduct Phase 2a study evaluating CC-31244 for the treatment of hepatitis C - Asia market represents one of the largest hepatitis C virus carrier...
Cocrystal Pharma Reports 2018 First Quarter Financial Results and Provides Corporate Update
11 mai 2018 08h00 HE
|
Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, May 11, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
Cocrystal Pharma Announces 1-for-30 Reverse Stock Split
23 janv. 2018 09h15 HE
|
Cocrystal Pharma, Inc.
– Reverse stock split positions Company to uplist to the NASDAQ Capital Market in Q1 2018 – – Company expects to commence Phase 2a study in Q1 2018 for lead program, CC-31244, for the treatment of...